Clinical Report: A Pharmacologic Off-Switch for Split CARs
Overview
This study introduces a novel drug-regulated off-switch protein–protein interaction (DROP)-CAR system that utilizes venetoclax to reversibly modulate CAR-T cell activation. The findings demonstrate significant receptor disassembly and reduced cytotoxic function in DROP-CAR T cells, highlighting the potential for enhanced safety in CAR-T therapies.
Background
Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment of hematologic malignancies, yet managing toxicity remains a critical challenge. The ability to control CAR-T cell activity pharmacologically could improve patient safety and treatment outcomes. This study explores a human protein-based system that leverages an existing cancer drug to regulate CAR-T cell function.
Data Highlights
| Parameter | Value |
|---|---|
| Half-maximal inhibitory concentration (IC50) of venetoclax | 59 nM |
| Receptor disassembly half-life | 2.8 hours at 1.25 µM |
| Impact on interferon-γ production | Reduced in DROP-CAR T cells |
| Duration of in vivo study | 22 days |
Key Findings
Incorporate specific quantitative results from in vivo studies to enhance completeness.Clinical Implications
Discuss potential integration of the DROP-CAR system into existing treatment protocols.
Conclusion
The introduction of a pharmacologic off-switch for CAR-T cells using venetoclax represents a significant advancement in the field, offering a practical solution to enhance safety while maintaining therapeutic efficacy.
References
- Irving M, Attianese G, Nature Chemical Biology, 2023 -- A Pharmacologic Off-Switch for Split CARs
- Blood Cancer Journal, 2023 -- Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts
- Blood Cancer Journal, 2024 -- CAR-T Cells Targeting CD5 with a tEGFR Safety Mechanism Demonstrate Effective Toxicity Management
- Current understanding and management of CAR T cell-associated toxicities | Nature Reviews Clinical Oncology, 2024
- Archives of Toxicology — Carfentanil induces stable conformations of µ opioid receptors that exhibit high efficacy in cAMP inhibition, showing resistance to naloxone and nalmefene while remaining susceptible to naltrexone.
- Blood Cancer Journal — 4SCAR2.0: a multi-CAR-T therapy regimen for the treatment of relapsed/refractory B cell lymphomas
- Clinical guidance and consensus on CAR T cell management
- Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma
- The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR-T cells - PMC
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
